News - GlaxoSmithKline, Benlysta, Biotechnology

Filter

Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity

04-04-2013

US and European rheumatologists surveyed by health care advisory firm Decision Resources indicate that…

Anthera PharmaceuticalsAnti-Arthritics/RheumaticsBenlystaBiotechnologyblisibimodepratuzumabEuropeGlaxoSmithKlineImmunomedicsImmuPharmaLupuzorMarkets & MarketingNorth AmericaPharmaceuticalUCB

Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR

25-10-2012

In the systemic lupus erythematosus (SLE) drug market, Human Genome Sciences/GlaxoSmithKline's (LSE:…

BenlystaBiotechnologyGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRare diseases

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million

11-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Barriers to overcome in lupus drug development

22-07-2012

It has taken the lupus research community over 50 years to produce a new therapy. Although it is now…

Anthera PharmaceuticalsBenlystaBiotechnologyblisibimodGlaxoSmithKlineImmunologicalsPharmaceuticalResearch

New briefs: GSK extends HGS tender offer; J&J plans for $600 million charge; FDA delays prophylactic Truvada

10-06-2012

In the continuing saga of its hostile takeover bid for its partner on lupus drug Benlysta (belimumab),…

BenlystaBiotechnologyFinancialGilead SciencesGlaxoSmithKlineHuman Genome SciencesJohnson & JohnsonLegalMergers & AcquisitionsPharmaceuticalRegulationRisperdalTruvada

Zacks analysts view progress of GSK bid for Human Genome Sciences

05-06-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) recently announced that the waiting period with respect to…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

09-05-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Benlysta continues to penetrate lupus market one year post-launch; report

08-05-2012

More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

Benlysta gaining bigger US market share

13-12-2011

Over half of surveyed US rheumatologists surveyed by Decision Resources unit BioTrends have initiated…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingNorth AmericaPharmaceuticalRare diseases

Important decision for the biotech industry from UK Supreme Court

03-11-2011

The UK’s Supreme Court yesterday gave guidance on the patentability of gene sequence inventions,…

BenlystaBiotechnologyEli LillyEuropeGlaxoSmithKlineHuman Genome SciencesLegalPatentsPharmaceutical

GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports

18-10-2011

Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Back to top